The current landscape of 1,2,3‐triazole‐(fused) six‐membered nitrogen‐containing heteroaromatic ring hybrids with anticancer therapeutic potential DOI Open Access

Zhi Xu,

Rongqiang Li,

Zhiwei Huang

et al.

Archiv der Pharmazie, Journal Year: 2024, Volume and Issue: 358(1)

Published: Dec. 30, 2024

Cancer, characterized by uncontrolled growth and spread of abnormal cells potentially influencing almost all tissues in the body, is one most devastating lethal diseases throughout world. Chemotherapy principal approaches for cancer treatment, but multidrug resistance severe side effects represent main barriers to success therapy, creating a vital need develop novel chemotherapeutic agents. The 1,2,3-triazole moiety can be conveniently constructed "click chemistry" could exert diverse noncovalent interactions with various enzymes cells. Hence, fascinating anticancer pharmacophores. Moreover, also serve as powerful ligation tool complex molecular architectures increase efficacy lead molecules. Notably, 1,2,3-triazole-containing hybrids intriguing structural variations target different biological components simultaneously, highlighting their potential treatment eradication cancer. This review outlines current landscape 1,2,3-triazole-(fused) six-membered nitrogen-containing heteroaromatic ring hybrids, inclusive 1,2,3-triazole-quinazolines, 1,2,3-triazole-quinazolinones, 1,2,3-triazole-quinolines, 1,2,3-triazole-quinolones, 1,2,3-triazole-pyridines, 1,2,3-triazole-pyrimidines, therapeutic potential, explores mechanisms action, critical aspects design well structure-activity relationships (SARs), covering articles published from 2021 present, pave way development innovative efficient interventions therapy.

Language: Английский

Quinazolinone-linked triazole conjugates: Synthesis, biological evaluation, and in silico studies DOI

Udhav V. Mhetre,

Amruta N. Bhagat,

Shyam V. Londhe

et al.

Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 141594 - 141594

Published: Jan. 1, 2025

Citations

0
Development of 1,2,3‐Triazolopyridazinone Derivatives as Potential Caspase 3 and Apoptosis Inducers: Design, Synthesis and Anticancer Activity Studies DOI Creative Commons
Güler Yagiz Erdemir, Ali Kuruçay, Burhan Ateş

et al.

Journal of Biochemical and Molecular Toxicology, Journal Year: 2025, Volume and Issue: 39(3)

Published: March 1, 2025

ABSTRACT Herein, the synthesis, anticancer activity and apoptotic pathways of 1,2,3‐triazolopyridazinones compounds, which are similar to DNA bases not previously found in literature have been investigated. To achieve this goal, it is designed hybrid molecules combining triazole pyridazinone/pyridazithione structures, bearing a lipophilic group (benzyl/phenyl) at one position benzene with electron withdrawing or donating groups five positions, high pharmacophoric properties on same scaffold structure. The representative compounds series 5a, 5c, 6a 8c exhibited higher than other cisplatin control against breast (MCF‐7) lung (A549) cell lines. These were less toxic when tested noncancerous L929 line. In addition, effect mechanisms these confirmed by AO/EB staining caspase 3 results. findings indicate that some derivatives could be effective therapeutic agents for treatment cancer disease an apoptosis‐promoting.

Language: Английский

Citations

0
Synthesis of Quinazoline‐1,3,4‐Oxadiazole Linked 1,2,3‐Triazole Hybrids as Potent EGFR Targeting Antilung Cancer Agents: In Vitro, In Silico, and DFT Studies DOI

Sampath peddapelli,

Mahadev Bandgar,

Ravikumar Kapavarapu

et al.

ChemistrySelect, Journal Year: 2025, Volume and Issue: 10(16)

Published: April 1, 2025

Abstract This research focuses on the design and synthesis of novel quinazoline‐1,3,4‐oxadiazole linked 1,2,3‐triazoles. Subsequently, it investigates their in vitro inhibitory effects EGFR kinases anticancer efficacy against lung cancer cell lines A‐549 H1299. Compared to primary compound, erlotinib, most tested compounds demonstrated superior efficacy. The 2‐(((1‐(3,5‐difluorophenyl)‐1 H ‐1,2,3‐triazol‐4‐yl)methyl)sulfonyl)‐5‐(quinazoline‐5‐yl)‐1,3,4‐oxadiazole, 2‐(((1‐(3,5‐dichlorophenyl)‐1 ‐1,2,3‐triazol‐4‐yl)methyl)sulfonyl)‐5‐(quinazolin‐5‐yl)‐1,3,4‐oxadiazole, 2‐(((1‐(4‐fluorophenyl)‐1 ‐1,2,3‐triazol‐4‐yl)methyl)sulfonyl)‐5‐(quinazoline‐5‐yl)‐1,3,4‐oxadiazole showed strong activity both with IC 50 values ranging from 2.62 ± 0.65 4.21 0.24 µM. exhibited notable kinase 0.34 0.03, 0.36 0.04, 0.43 0.02 µM, respectively. In Silico docking experiments were conducted assess molecular interactions more potent drugs human epidermal growth factor receptor, (PDB: 4HJO) proteins, which included a co‐crystallized ligand (erlotinib). results indicated that six active significantly higher binding energies compared standard medications. SWISS/ADME was used estimate pharmacokinetic profile compounds. Geometric optimization also determine structural characteristics compound ‐1,2,3‐triazol‐4‐yl)methyl)sulfonyl)‐5‐(quinazolin‐5‐yl)‐1,3,4‐oxadiazole. electrostatic potential (MEP) HOMO‐LUMO energy gap determined.

Language: Английский

Citations

0
The current landscape of 1,2,3‐triazole‐(fused) six‐membered nitrogen‐containing heteroaromatic ring hybrids with anticancer therapeutic potential DOI Open Access

Zhi Xu,

Rongqiang Li,

Zhiwei Huang

et al.

Archiv der Pharmazie, Journal Year: 2024, Volume and Issue: 358(1)

Published: Dec. 30, 2024

Cancer, characterized by uncontrolled growth and spread of abnormal cells potentially influencing almost all tissues in the body, is one most devastating lethal diseases throughout world. Chemotherapy principal approaches for cancer treatment, but multidrug resistance severe side effects represent main barriers to success therapy, creating a vital need develop novel chemotherapeutic agents. The 1,2,3-triazole moiety can be conveniently constructed "click chemistry" could exert diverse noncovalent interactions with various enzymes cells. Hence, fascinating anticancer pharmacophores. Moreover, also serve as powerful ligation tool complex molecular architectures increase efficacy lead molecules. Notably, 1,2,3-triazole-containing hybrids intriguing structural variations target different biological components simultaneously, highlighting their potential treatment eradication cancer. This review outlines current landscape 1,2,3-triazole-(fused) six-membered nitrogen-containing heteroaromatic ring hybrids, inclusive 1,2,3-triazole-quinazolines, 1,2,3-triazole-quinazolinones, 1,2,3-triazole-quinolines, 1,2,3-triazole-quinolones, 1,2,3-triazole-pyridines, 1,2,3-triazole-pyrimidines, therapeutic potential, explores mechanisms action, critical aspects design well structure-activity relationships (SARs), covering articles published from 2021 present, pave way development innovative efficient interventions therapy.

Language: Английский

Citations

1